UNSPSC 51362803: Methaqualone hydrochloride

This classification denotes an anxiolytic with the molecular formula C16H14N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RJQ4G25ZRH, chemically known as 3,4-dihydro-2-methyl-4-oxo-3-o-tolylquinazoline but more generally known as methaqualone hydrochloride, which bears US NIH Compound Identifier 6292. European Medicines Agency schedules Methaqualone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03212MIG.

Most nations, for tariff and trade purposes, schedule methaqualone hydrochloride under HS 29335500 and SITC 51576. As of Q4 2014, METHAQUALONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Methaqualone hydrochloride bears US NLM identifiers UMLS ID C1522632 and NCI Concept Code C2484. SMILES: CC1CCCCC1N2C(NC3CCCCC3C2=O)C.CL.

UNSPSC 51362803 Methaqualone hydrochloride is a Commodity code that nominally covers a specific controlled pharmaceutical substance, but recent state and local procurement activity under this code shows minimal alignment with that narrow definition. The three most recent opportunities posted against this code span naloxone distribution, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and OTC products—none of which involve methaqualone hydrochloride itself. State and local governments tag opportunities with UNSPSC codes that often diverge from actual scope, and this code's recent activity reflects broader pharmaceutical procurement rather than the specific controlled substance named. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP, which includes participating state and local facilities in Oregon and other jurisdictions).

Recent activity clusters in Florida and the upper Midwest, with the Texas HHS RFI representing early-stage market intelligence gathering rather than a formal competitive solicitation. The Seminole County IFB (Solicitation IFB60459723LAS, response deadline July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS RFI (HHS0017013, posted April 3, 2026) explored vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established multiple-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities, with pricing weighted at 75 percent of evaluation criteria and mandatory use of three authorized wholesalers. The code shows little relevant recent activity for methaqualone hydrochloride specifically, and the opportunities posted suggest a systemic mislabeling or overly broad code assignment by the issuing bodies rather than genuine demand under this Commodity's stated scope.